<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883906</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0229</org_study_id>
    <nct_id>NCT03883906</nct_id>
  </id_info>
  <brief_title>Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant</brief_title>
  <official_title>Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoxworth Blood Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn more about the use of viral specific
      T-lymphocytes (VSTs) to prevent viral infections that may happen after allogeneic stem cell
      transplant. Allogeneic means the stem cells come from another person. VSTs are cells
      specially designed to fight viral infections that may happen after a stem cell transplant
      (SCT).

      Stem cell transplant reduces your ability to fight infections. Viral infections are a common
      problem after transplant and can cause significant complications. Moreover, treatment of
      viral infections is expensive and time consuming, with families often administering prolonged
      treatments with intravenous anti-viral medications, or patients requiring prolonged
      admissions to the hospital. The medicines can also have side effects like damage to the
      kidneys or reduction in the blood counts, so in this study we are trying to find a way to
      prevent these infections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Toxicity</measure>
    <time_frame>up to 30 days after last VST infusion</time_frame>
    <description>Participants will be assessed for the presence of a toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute Graft-Vs-Host Disease (aGVHD)</measure>
    <time_frame>up to 30 days after last VST infusion</time_frame>
    <description>Participants will be assessed for the presence of aGVHD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral infection</measure>
    <time_frame>up to 30 days after last VST infusion</time_frame>
    <description>Participants will be assessed for the presence of viral infection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Allogeneic Stem Cell Transplant</condition>
  <condition>Viral Infection</condition>
  <arm_group>
    <arm_group_label>Viral Specific T-cells (VSTs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Viral Specific T-cells (VSTs)</intervention_name>
    <description>VSTs will be infused into stem cell transplant recipients</description>
    <arm_group_label>Viral Specific T-cells (VSTs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipient must be at least 21 days after stem cell infusion

          -  Clinical status must allow tapering of steroids to &lt; 0.5mg/kg prednisone or other
             steroid equivalent

        Exclusion Criteria:

          -  Patients who have developed viral infection or reactivation will be ineligible for
             prophylactic infusions of VSTs

          -  Active acute GVHD grades II-IV

          -  Uncontrolled relapse of malignancy

          -  Infusion of ATG or alemtuzumab within 2 weeks of VST infusion. Additionally, in
             patients who received alemtuzumab as part of their conditioning regimen, alemtuzumab
             levels will be collected in the second week following stem cell infusion. The level
             must be less than, or equal to, 0.15 prior to infusion of VSTs. In patients with level
             greater than 0.15, alemtuzumab levels can be checked serially until a level â‰¤ 0.15 is
             obtained. They would become eligible for prophylactic VST infusion at that point if
             there is still no evidence of viral infection at that time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Grimley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celeste Dourson, MS</last_name>
    <phone>(513) 636-7679</phone>
    <email>Celeste.Dourson@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Wilhelm, BS</last_name>
    <phone>(513) 803-1102</phone>
    <email>Jamie.Wilhelm@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Dourson, MS</last_name>
    </contact>
    <investigator>
      <last_name>Michael Grimley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

